Document Detail

Treatment options for primary splenic low-grade non-Hodgkin's lymphomas.
MedLine Citation:
PMID:  15595997     Owner:  NLM     Status:  MEDLINE    
The purpose of this comparative study was to evaluate the response of primary splenic low-grade non-Hodgkin's lymphomas (NHL) to chemotherapy, splenectomy, and chemotherapy combined with splenectomy in order to elaborate the optimum treatment modality. A total of 104 patients (age range: 15-82 years) with primary low-grade B-cell NHL of the spleen were comprised by our study. Stage IV disease was determined in 102 (98.1%) cases. Regarding the treatment modality, splenectomy was performed in 14 patients, early splenectomy and single-agent chemotherapy in 15, early splenectomy and combined chemotherapy in 19, single-agent chemotherapy in 23, and combined chemotherapy in 33. In the above-mentioned order, complete remission rate was following: none, 40.0, 31.6, 21.8, and 18.2%. Partial remissions were achieved in 85.7, 46.7, 57.9, 30.4, and 69.7% of cases, respectively. The median remission duration turned out to be longer (74.5 months) in the group of patients with complete remissions attained by means of splenectomy and combined chemotherapy. Local relapses in the spleen developed in 19 (72.7%) patients treated with combined chemotherapy and in 9 (90.0%), who had undergone single-agent chemotherapy. The 5-year overall survival was 54.4% after splenectomy, 39.4% after single-agent chemotherapy, and 37.1% after combined chemotherapy, being significantly higher (P <0.05) after splenectomy and single-agent chemotherapy (67.2%), and splenectomy followed by combined chemotherapy (64.7%). Early splenectomy combined with chemotherapy is the optimum treatment option for primary low-grade NHL of the spleen because of the superiority in complete remission rate, remission duration, and in overall survival rate. Splenectomy leads to somatic compensation of patients, makes impossible local relapsing in the spleen, prevents continuous dissemination from the primary tumor site, and mostly corrects cytopenias, creating better conditions for chemotherapy.
V Gh Musteata; I T Corcimaru; I A Iacovleva; L Z Musteata; I S Suharschii; L T Antoci
Related Documents :
23609587 - Abdominal radical trachelectomy: a safe and feasible option for fertility preservation ...
10606897 - The immunosuppression and potential for ebv reactivation of fludarabine combined with c...
20625137 - High rates of durable responses with anti-cd22 fractionated radioimmunotherapy: results...
3576707 - Intensive chemotherapy regimen in high-grade non hodgkin's lymphomas.
19212117 - Radiofrequency ablation versus resection for resectable colorectal liver metastases: ti...
19251377 - Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Clinical and laboratory haematology     Volume:  26     ISSN:  0141-9854     ISO Abbreviation:  Clin Lab Haematol     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-14     Completed Date:  2005-06-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7907061     Medline TA:  Clin Lab Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  397-401     Citation Subset:  IM    
Department of Hematology and Oncology, State Medical and Pharmaceutical University N. Testemitanu, Chisinau, Republic of Moldova.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Lymphoma, Non-Hodgkin / drug therapy,  therapy*
Middle Aged
Splenic Neoplasms / drug therapy,  therapy*
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Levels of soluble forms of ICAM and VCAM in patients with myelodysplastic syndromes and their progno...
Next Document:  Audit of bone marrow aspirates and trephine biopsies in multiple myeloma--a single centre study.